2020-11-16T11:03:40-06:00 2019-12-31 861065772 Deloitte Tax LLP 695 Town Center Drive Suite 1200 Costa Mesa CA 926261924 990 2019-01-01 330328688 La Jolla Institute for Immunology LAJO 8587526500 9420 Athena Circle La Jolla CA 920371387 Michael Dollar CFO 8587526500 2020-11-16 1 Rebecca L Lyons P01487105 7144367100 24.3.244.63 2020-11-16 10:49:16 ES P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 92426507D63AB8DCB9F8A2EED31D9394E8F3722B 2019 2021-01-29 14:40:06Z Michael Dollar 9420 Athena Circle La Jolla CA 920371387 68642455 0 X www.lji.org X 1988 CA Biomedical research dedicated to improving human health through studies of the immune system. 26 25 479 65 710139 112962 50878842 58096830 5548673 7349335 -249669 1740790 1788428 1455500 57966274 68642455 8250 769190 0 0 32116302 34553331 0 0 921617 28212354 34836716 60336906 70159237 -2370632 -1516782 36958419 50722461 11952548 27233372 25005871 23489089 At La Jolla Institute for Immunology, our scientists focus on understanding how the immune system works in order to promote human health and prevent disease. Our discoveries apply to many diseases, ranging from diabetes to heart disease, infectious diseases to cancer. 0 0 60998379 769190 7349335 La Jolla Institute for Immunology ("LJI") is a private, nonprofit medical research organization that is recognized as a world leader in comprehensive research dedicated to understanding the intricacies and power of the immune system and applying that knowledge toward its goal of Life Without Disease. The Institute is home to 21 independent laboratories, each operated by a leading scientist handpicked for their creativity and pioneering spirit. Each of these labs is dedicated to understanding the far-reaching influence of the immune system and to training to the next generation of scientists, to promote human health and prevent a wide range of diseases. 60998379 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 1 160 0 1 479 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 26 25 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR CA FL GA HI IL KS KY MA MD MI MN MS NC NH NJ NM NY OH OR PA RI SC TN TX UT VA WI WV X Michael Dollar 8587526500 9420 Athena Circle La Jolla CA 920371387 Mitchell Kronenberg President & CSO 40.00 0.00 X X 541764 0 85071 Richard S Bodman Director 2.00 0.00 X 0 0 0 Mark V Bowles Director 2.00 0.00 X 0 0 0 David A Brenner MD Director 2.00 0.00 X 0 0 0 Anthony Carr Director 2.00 0.00 X 0 0 0 Kristine Charton JD Director 2.00 0.00 X 0 0 0 Barton J Cohen Director 2.00 0.00 X 0 0 0 Michael D Coit Director 2.00 0.00 X 0 0 0 David Dominguez Director 2.00 0.00 X 0 0 0 Robert C Dynes PhD Director 2.00 0.00 X 0 0 0 Franois Ferre PhD Director 2.00 0.00 X 0 0 0 Genevive T Jacobs Director 2.00 0.00 X 0 0 0 Robert W Mahley MD PhD Director 2.00 0.00 X 0 0 0 John E Major Chair Director 2.00 0.00 X 0 0 0 Gail K Naughton PhD Director 2.00 0.00 X 0 0 0 Hunt Pettit Director 2.00 0.00 X 0 0 0 Mitsuo Satoh PhD Director 2.00 0.00 X 0 0 0 Sandor W Shapery JD Director 2.00 0.00 X 0 0 0 Larry S Spitcaufsky Director 2.00 0.00 X 0 0 0 Lynda Stuart MD PhD Director 2.00 0.00 X 0 0 0 Paul Thiel Director (Start 08/2019) 2.00 0.00 X 0 0 0 Thomas L Tullie Director 2.00 0.00 X 0 0 0 Pamela K Wasserman MPH Director 2.00 0.00 X 0 0 0 David R Webb PhD Director 2.00 0.00 X 0 0 0 Vanessa V Wertheim PhD MBA RN Director 2.00 0.00 X 0 0 0 Eric V Zwisler Director 2.00 0.00 X 0 0 0 Michael Dollar CFO (Start 06/24/2019) 40.00 0.00 X 146986 0 13682 Stephen Wilson EVP, COO & CTO 40.00 0.00 X 386862 0 98035 Michael Croft Director Scientific Affairs 40.00 0.00 X 323176 0 71232 Alessandro Sette Division Head/Center Head/Prof 40.00 0.00 X 425416 0 96752 Catherine Hedrick Professor 40.00 0.00 X 325110 0 68183 Klaus Ley Division Head/Professor 40.00 0.00 X 316529 0 58977 Stephen P Schoenberger Professor 40.00 0.00 X 288333 0 82469 Hilde Cheroutre Division Head/Professor 40.00 0.00 X 294002 0 55624 Jennifer K Keyes CFO (End 06/18/2019) 40.00 0.00 X 215861 0 21211 3264039 0 651236 54 1 1 0 Finley & Cook 601 N Broadway PO Drawer 1447 Shawnee OK 748021447 ERP software 303686 A&A Labs LLC 9863 Pacific Heights Blvd Ste F San Diego CA 92121 Lab Supplies 273099 Pestotnik LLP 501 West Broadway Ste 1025 San Diego CA 92101 Patient Related (Legal and Prof. Sv) 121902 Moss-Adams LLP PO Box 101822 Pasadena CA 911891822 Auditor (Audit Organization Financial) 112300 1903 Solutions LLC 2549 Eastbluff Dr Ste 378 Newport Beach CA 92660 Computer Hardware/Fortigate and security 109957 5 38900595 19196235 58096830 Consortium Revenue 900099 7349335 7349335 7349335 444536 444536 160837 160837 1296254 0 1296254 1296254 1296254 Technical Services 541900 441832 441832 Building Management 541900 268307 268307 Contract Service 900099 259949 259949 324575 324575 1294663 68642455 7349335 710139 2486151 19009 19009 750181 750181 1666808 1414208 216919 35681 237072 201156 35916 24931232 21075216 3394139 461877 2572417 2155532 358357 58528 3322820 2861979 379780 81061 1822982 1527551 253955 41476 837238 572941 264297 312402 312402 327513 67222 181085 79206 246802 6361 238855 1586 155030 107069 29477 18484 1682425 565763 1107760 8902 7137151 6479208 623523 34420 728607 570409 126833 31365 211092 176687 25546 8859 1886851 1758919 127932 219493 202123 16275 1095 Lab Supplies Service 10015899 10015899 Consortium 6021321 6021321 Other Expenses 2170425 2170425 Manuscripts Costs 1693741 1200978 433686 59077 1190726 1078222 112504 70159237 60998379 8239241 921617 1667 0 4256004 7517882 10565755 14223696 32144 17858 614032 1008011 1298030 949703 38240150 20489441 6890783 17750709 13300004 9254602 36958419 50722461 9643229 16281365 2309319 3213029 0 7738978 11952548 27233372 X 16604913 15627555 8400958 7861534 25005871 23489089 36958419 50722461 -1516782 0 X 0 1 X 1 1 1 X The University of California San Diego San Diego CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 92333 92333 0 7613303 4280642 3332661 30519514 16116466 14403048 15000 15000 17750709 X 68642455 0 68642455 0 68642455 70159234 0 70159234 3 3 70159237 Part X, Line 2: The Institute is subject to federal and state income taxes on unrelated business income as defined under IRC Sections 511 through 515. For each of the years ended December 31, 2019 and 2018, taxes are recorded when paid and no provision for income tax has been made. The Institute had no unrecognized tax benefits or liabilities as of December 31, 2019 and 2018. Part XII, Line 4b - Other Adjustments: ROUNDING 3. Sub-Saharan Africa 0 0 Program Services Research 15298 Europe (Including Iceland & Greenland) 0 0 Program Services Research 628654 South Asia 0 0 Program Services Research 106229 0 0 0 0 0 0 750181 0 750181 Sub-Saharan Africa RESEARCH 6000 South Asia RESEARCH 106229 Europe (Including Iceland & Greenland) RESEARCH 79219 Europe (Including Iceland & Greenland) RESEARCH 11040 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium RESEARCH 167793 Europe (Including Iceland & Greenland) RESEARCH 69938 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, RESEARCH 9298 Europe (Including Iceland & Greenland) RESEARCH 300664 0 0 0 0 0 0 Part I, Line 2: Detailed invoices are received, compared to budgeted subcontract amounts, and approved, prior to payment by LJI faculty. LJI may request additional detail or support for any unusual items. Additionally, scientific reports from subcontractors are received and reviewed by LJI investigators. Part III Accounting Method: Part I, Line 3, Column (F): Accrual method Part II, Line 1 Accrual method 1 JDRF 5665 Oberline Drive Suite 106 San Diego CA 92121 231907729 501(c)(3) 6000 To Cure Type I Diabetes 1 0 Part I, Line 2: LJI supports certain charities whose mission is inline with our research. This support is not in the form of grants, but rather contributions. Therefore, documentation exists over payment of contributions. Formal monitoring and selections procedures not considered necessary. X 1 1 X X X X 1 0 0 0 0 0 0 0 0 Mitchell Kronenberg President & CSO 513979 0 0 0 27785 0 61000 0 24071 0 626835 0 0 0 Michael Dollar CFO (Start 06/24/2019) 125923 0 0 0 21063 0 0 0 13682 0 160668 0 0 0 Stephen Wilson EVP, COO & CTO 366469 0 0 0 20393 0 60225 0 37810 0 484897 0 0 0 Michael Croft Director Scientific Affairs 319939 0 0 0 3237 0 48750 0 22482 0 394408 0 0 0 Alessandro Sette Division Head/Center Head/Prof 403175 0 0 0 22241 0 61000 0 35752 0 522168 0 0 0 Catherine Hedrick Professor 307584 0 0 0 17526 0 46892 0 21291 0 393293 0 0 0 Klaus Ley Division Head/Professor 311770 0 0 0 4759 0 46933 0 12044 0 375506 0 0 0 Stephen P Schoenberger Professor 285092 0 0 0 3241 0 46717 0 35752 0 370802 0 0 0 Hilde Cheroutre Division Head/Professor 289399 0 0 0 4603 0 43606 0 12018 0 349626 0 0 0 Jennifer K Keyes CFO (End 06/18/2019) 120847 0 0 0 95014 0 15073 0 6138 0 237072 0 0 0 Part I, Line 1a The President/Chief Scientific Officer took one first class business related flight which was in accordance with LJI Policy. No amount was treated as taxable to the listed person. Part II, Line 10 Jennifer K. Keyes, former, CFO, received a severance payment of $85,833 in 2019. SEE PART V X 100000 17858 0 1 1 17858 SEE PART V 0 Sch L, Part II, Loans to and / or From Interested Persons: (a) Name of Person: Catherine Hedrick(b) Relationship Between Interested Person and Organization:Highest Compensated Employee(c) Purpose of Loan: Faculty Housing Loan(d) Loan to or From the Organization: From(e) Original Principal Amount $100,000(f) Balance Due: $17,858(g) In Default: No(h) Approved by board or Committee: Yes(i) Written Agreement: Yes Sch L, Part IV, Business Transactions Involving Interested Persons: (a) Name of Person: Hilde Cheroutre(b) Relationship Between Interested Person and Organization: Spouse of President and CSO (c) Amount of Transaction: $294,002(d) Description of Transaction: Full Time Employee(e) Sharing of Organization Revenues?: No(a) Name of Person: Kyowa Kirin Pharmaceutical Research, Inc.(b) Relationship Between Interested Person and Organization:KKR is a Substantial Contributor to the Organization.(c) Amount of Transaction: $3,326,659(d) Description of Transaction: Research Funding, Facility Rent, Cost Reimbursements (e) Sharing of Organization Revenues?: No Form 990, Part III, Line 4a; Dr. Erica Ollmann Saphire, one of the world's leading experts in pandemic and emerging viruses, joined LJI faculty in the spring of 2019. Dr. Saphire directs an international consortium analyzing antibody therapeutics and vaccine responses. Her lab studies the three-dimensional structures of viral proteins to understand, at the molecular level, how viruses like Ebola, Marburg and Lassa are so deadly. In a series of groundbreaking discoveries, her team has determined the molecular structures of the Ebola, Sudan, Bundibugyo, Marburg, LCMV and Lassa virus surface glycoproteins; how these viruses suppress immune function and where human antibodies dock to defeat these viruses. A widely recognized structural biologist, Dr. Saphire has established a molecular imaging facility at La Jolla Institute for cryo-electron microscopy (cryo-EM). The extremely detailed images produced by cryo-EM reveal precisely how essential mechanisms of the immune system operate. Bringing Dr. Saphire's expertise and state-of-the-art cryo-EM capabilities to the Institute will help LJI scientists drive pioneering advances from molecular structure to human immunology to global health. Among the flood of research papers published by scientists and scholars in academic journals year in and year out, by some estimates their numbers now exceed 2,500,000 papers annually; the research contributions of scientists at La Jolla Institute for Immunology stand out for their global impact. Four researchers, or 19 percent of La Jolla Institute for Immunology's faculty, have been named in the Highly Cited Researchers 2019 list from the Web of Science Group. The 2019 Highly Cited Researchers list, released November 19 by the Web of Science Group, identifies scientists who produced multiple papers ranking in the top 1% by citations for their field and year of publication, demonstrating significant research influence among their peers. La Jolla Institute for Immunology faculty on the list include Professor Shane Crotty, Ph.D., whose ground breaking work on the immunology underlying vaccines earned him a spot on the list for the fourth year in a row; Professor Alessandro Sette, Dr. Biol.Sci., whose sustained efforts to systematically dissect the immune response to a wide range of microbes and allergens has a tremendous impact on the field of immunology, made the list for the second year. This year, they are joined by Professor Bjoern Peters, Ph.D., who helped established the Immune Epitope Database, a free, searchable site that houses data from more than 1.6 million experiments, making it a one-stop shop for understanding and predicting the body's response to viruses, bacteria, cancer, allergens and more, and Professor Anjana Rao, Ph.D., whose pioneering insights into the fundamentals of T cell biology have the potential to successfully address T cell exhaustion, which, in the past, has limited the success of cancer immunotherapies. In 2019, professors Crotty and Sette were named as Fellows of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. Dr. Crotty was elected an AAAS fellow in recognition of his distinguished contributions to the field of vaccine immunology, particularly defining and characterizing T follicular helper (Tfh) cells and their roles in humoral immunity. Dr. Sette was recognized for his distinguished contributions to the field of immunology, particularly for providing insights into T-cell specificity and immune-profiling of T-cells in human disease, and for pioneering immuno-informatics. Dr. Crotty also was selected to receive the 2019 Frederick W. Alt Award for New Discoveries in Immunology for his pioneering insights in the fundamentals of what makes a good immune response to help custom-engineer vaccine candidates so they elicit a protective immune response. The award is given annually to a former Cancer Research Institute postdoctoral fellow in recognition of outstanding success in academia or industry for research that has had a major impact in the field of immunology. The American Association of Immunologists (AAI) has named LJI President and Chief Scientific Officer Dr. Mitchell Kronenberg, a world expert in T cell biology, as an AAI 2019 Distinguished Fellow. He is among 52 immunologists, including five Nobel Laureates, selected for the inaugural class of fellows. Election as a Distinguished Fellow is among the highest honors bestowed by AAI and recognizes members for distinguished careers and outstanding scientific contributions as well as their service to AAI and the immunology community. Dr. Kronenberg is best known for his extensive studies of a subset of specialized T cells known as invariant natural killer T (iNKT) cells and their brethren, mucosal-associated invariant T (MAIT) cells. Both cell types are an integral part of the innate immune response, which reacts almost immediately to foreign invaders. Sara McArdle, Ph.D., a microscopy specialist at La Jolla Institute for Immunology (LJI) who helps scientists take advantage of the latest imaging technology by bridging the gap between engineering, software development, data processing and biology, was selected as one of seventeen "Imaging Scientists" by the Chan Zuckerberg Initiative (CZI). CZI initiated the Imaging Scientists program to break down the walls between disciplines and empower biologists to reap the most benefit from new technical advances in the field of imaging. It funds imaging specialists who can move creatively between different fields, from physics and medicine, to engineering and biology. In 2019, La Jolla Institute for Immunology (LJI) has been awarded a $22 million contract renewal over seven years from the National Institutes of Health (NIH) to host and expand the Immune Epitope Database (IEDB). The database is the world's most comprehensive collection of scientific data on how the immune system responds to a wide range of infectious agents, allergy-causing substances, and other stimuli that activate the immune system. A La Jolla Institute-led consortium was awarded up to $35 million by the National Institutes of Health. It brings together experts from around the world to streamline and accelerate the development of immunotherapeutics against emerging and re-emerging viral threats under the leadership of Dr. Saphire. The Viral Immunotherapeutic Consortium (VIC) continues a tremendously successful international program that Dr. Saphire initiated and directed to bridge the gap between results obtained in the lab and effective treatments that can be deployed in the field. The consortium, now headquartered at La Jolla Institute for Immunology, will specifically focus on the clinical development of therapeutic candidates identified by the VIC for Ebola and other related filoviruses, arenaviruses, such as Lassa virus as well as a third major global threat, alphaviruses, which infect millions of people across the world. 2019 Notable Research Results In 2019, LJI research teams made discoveries meriting publication in leading peer-reviewed scientific journals 147 papers in all, continuing a trend of very high productivity. 45 of them appeared in high impact journals, which is a measure of the research's pioneering nature and influence. Together, they illustrate the range and power of immunology research, the caliber of LJI's faculty and their impact on a broad group of human health issues. Some of the highlights among papers published in 2019 include: Dr. Crotty showed that new HIV vaccine delivery strategy appears to enhance the protective immune response in a preclinical model. He and his colleagues discovered that delivering an HIV vaccine in small doses over a series of days leads to a stronger immune response than when the same vaccine is given all at once. A similar escalating dose method could be the best way to administer an HIV vaccine in future clinical trials. In an unrelated study, Dr. Crotty and his team discovered why some kids are prone to repeated bouts of strep throat while others appear to be more or less immune. His findings suggest that recurrent tonsillitis is a multifactorial disease where immunological factors combined with an underlying genetic susceptibility allow group A strep to invade the throats of certain individuals time and again. Gaining a better understanding of why some children fail to develop protective immunity also opens the door to developing a vaccine to protect against strep throat, the researchers predict. Form 990, Part III, Line 4a; Dr. Anjana Rao and her team devised a strategy to counteract T cell exhaustion in CAR T cancer therapies. A growing number of cancer patients are being offered a promising new treatment called CAR T cell therapy. In this therapy, a patients' own T cells are removed and genetically engineered to better recognize cancer cells. The cells are then returned to the patient's body, where they can mount an immune response. CAR T-cell therapies have saved lives, but there has been a downside: T cells can get overstimulated over time and can stop working due to a phenomenon called T cell exhaustion. The scientists' new study shows that a family of proteins, called Nr4a transcription factors, have a prominent role in regulating the genes associated with T cell exhaustion. Using a mouse model, the scientists demonstrated that treating mice with CAR T cells lacking these Nr4a transcription factors led to smaller tumors and better survival. Dr. Saphire and her team revealed Lassa virus' soft spot. CAAs this year's Lassa fever outbreak in Nigeria is finally ebbing, the total tally came to more than 600 infected people, one-quarter of them dead. Thousands more die each year, uncounted in rural villages throughout West Africa. With an annual wave of infections and new viral strains emerging, it has never been more important to understand the characteristics of a broadly protective immune response in order to develop effective treatments, or better yet, a vaccine. A new study led by Instructor Kathryn Hastie, Ph.D., and Professor Erica Ollmann Saphire, Ph.D., identified and then reverse engineered the molecular properties shared by antibodies that are particularly efficient at inactivating or "neutralizing" the virus. The team's findings also revealed that most neutralizing antibodies bind to the same spot on the surface of Lassa virus, providing a map for rational vaccine design. A study by Dr. Pandurangan Vijayanand identified a type of T cell that possesses superior tumor killing potential. Immunotherapies hold promise as a way to prompt a patient's own immune system to fight cancer cells. Yet immunotherapies only work in about 30 percent of patientsand they can cause dangerous side effects. In their new study, LJI scientists collaborated with a team from the University of Southampton to better understand a group of immune cells called tissue-resident memory T cells (TRMs). These cells are known to help the body fight infection, but there is increasing evidence that they also play a key role in fighting tumors. According to the new Journal of Experimental Medicine study, published in the June 21, 2019 edition, TRMs are indeed key tumor fighters. These cells are unique for their ability to seek out and kill tumor cells without suffering from the common phenomenon of T cell "exhaustion." Competitive Research Grant Funding & Research Awards & Distinctions During 2019, LJI scientists worked with the support of hundreds of grants, contracts and fellowships. The granting or prime institutions included: AbViro, American Association for Cancer Research, American Diabetes Association, American Heart Association, Bill & Melinda Gates Foundation, Boston Children's Hospital, Cancer Research Institute, Celsense, Chan Zuckerberg Initiative, CIRM, Columbia University, Crohn's and Colitis Foundation, Cue BioPharma, Eli Lilly, Emergent, Evotec, Expres2ion fund, Gritstone, Human Vaccines Project, Icahn School of Medicine at Mount Sinai, Incyte Corporation, Jane Coffin Childs, Kiowa Kirin Pharmaceuticals Research Inc., Lurie Children's Hospital of Chicago, Lyell Immunopharma, Michael J. Fox Foundation, Nektar Therapeutics, Neon Therapeutics, Novo Nordisk, Ondek, Parker Institute, Pew Charitable Trust, Pfizer, RythRx Therapeutics, SBP Medical Discovery Institute, Scripps Research Institute, Takeda, Tremeau Pharmaceuticals, Tulane University, Turnstone, Ukko Inc., Umea University/EU Commission, University of Oxford, University of California Berkeley, University of California Los Angeles, University of California Riverside, University of California San Diego, University of Pennsylvania, University of Virginia, Vanderbilt University, Vasculitis Foundation, Washington University, St Louis, Zalgen, AALAS, Albert Einstein College of Medicine, American Association of Immunologists, Bristol-Myers Squibb, Cedars Sinai Medical Center, Chicago Biosolutions, Emory University, Flow Pharma, Integrated Biotherapeutics, International AIDS Vaccine Initiative, iTeos Therapeutics, Leukemia & Lymphoma Society, Medical College of Wisconsin/Doris Duke Charitable Foundation, Moores Cancer Center, National Institute for Biotechnology, National Institutes of Health, Naval Medical Research Center, Oregon University, Quality Biological, Inc., Regeneron Pharmaceuticals, Inc, University of Washington With new and recurring grant support, the Institute received more than $54 million in research funding in 2019, which is supplemented by corporate funding sources as well as philanthropic support. Form 990, Part VI, Section A, line 2 Mitchell Kronenberg, Ph.D. and Hilde Cheroutre have a family relationship. Form 990, Part VI, Section B, line 11b In accordance with written Institute Policy, a draft of Form 990 is provided to all Board Members for their review and comment approximately 10 days prior to filing. This provides an opportunity for members of the Board to ask questions and obtain additional information. Comments and suggested changes to the draft are incorporated into the final version of Form 990. Form 990, Part VI, Section B, line 12c The Institute administers three separate conflict of interest policies applying to 1) The Board of Directors, 2) Faculty and Senior Administration, and 3) An investigator financial conflict of interest policy required under National Institutes of Health Regulations. The Institute regularly and consistently monitors and enforces these policies in accordance with written procedures, which include the completion of disclosure forms by covered individuals, evaluation of completed forms by a designated conflict review officer, and as necessary, further evaluation and determination by a designated conflict review committee. If a conflict is determined, a management plan is designed and monitored for the specific situation. Such plan may require the covered individual to eliminate the conflict. Form 990, Part VI, Section B, line 15 Compensation decisions for the institute's CEO and other key employees are made annually. Adjustments, if any, typically take effect on a January 1st Cycle. For these purposes, the institute's Human Resources Department Obtains relevant market comparability data for each position on an annual Basis. The institute also periodically engages an independent compensation Consulting firm to perform compensation studies for key individuals and to Evaluate the institute's executive compensation and benefits programs for Reasonableness. In accordance with its charter, the compensation committee Of the board of directors reviews and discusses this information, and the Performance of the institute's CEO and key employees, and formulates Recommended compensation actions to the full board of directors. The board Of directors reviews these recommendations and related information in Deciding compensation levels for each position. Form 990, Part VI, Section C, line 19 The Institute makes its governing documents, Conflict of Interest Policy, and Financial Statements available to the public upon request. Summarized Financial data is also made available as part of the Institute's Annual Report, which is widely distributed, and can be downloaded from the Institute's web site.